Abstract
Stat-3 (Signal Transduction and Activator of Transcription) is a member of the Stat family of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus. This protein is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery. This review deals with the recent developments of peptides and peptidomimetics or even non-peptidic small molecules, able to bind to the SH2 domain of Stat-3, thus blocking its functions. Moreover, several compounds able to alter the Stat-3 pathway by inhibition of kinases upstream to Stat-3, or even with unknown targets, were reviewed.
Keywords: Antitumor agents, Stat-3, Peptide-based antagonists, Small molecules, Natural compounds
Current Medicinal Chemistry
Title: STAT 3 as a Target for Cancer Drug Discovery
Volume: 15 Issue: 9
Author(s): Luca Costantino and Daniela Barlocco
Affiliation:
Keywords: Antitumor agents, Stat-3, Peptide-based antagonists, Small molecules, Natural compounds
Abstract: Stat-3 (Signal Transduction and Activator of Transcription) is a member of the Stat family of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus. This protein is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery. This review deals with the recent developments of peptides and peptidomimetics or even non-peptidic small molecules, able to bind to the SH2 domain of Stat-3, thus blocking its functions. Moreover, several compounds able to alter the Stat-3 pathway by inhibition of kinases upstream to Stat-3, or even with unknown targets, were reviewed.
Export Options
About this article
Cite this article as:
Costantino Luca and Barlocco Daniela, STAT 3 as a Target for Cancer Drug Discovery, Current Medicinal Chemistry 2008; 15(9) . https://dx.doi.org/10.2174/092986708783955464
DOI https://dx.doi.org/10.2174/092986708783955464 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry MEMS and Microfluidics for Diagnostics Devices
Current Pharmaceutical Biotechnology Emerging Concepts in Diabetes: Mitochondrial Dynamics and Glucose Homeostasis
Current Diabetes Reviews Chemo-Radiation Association in Head and Neck Squamous Cell Carcinoma: Evidences and Criticisms
Current Drug Therapy Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Metal Ions and Metal Complexes in Alzheimer’s Disease
Current Pharmaceutical Design Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
Current Medicinal Chemistry Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters Patent Selections
Recent Patents on Biomarkers Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry